Published in J Acquir Immune Defic Syndr on August 15, 2005
Metabolic syndrome in HIV-infected patients from an urban, midwestern US outpatient population. Clin Infect Dis (2007) 2.34
Smoking-related health risks among persons with HIV in the Strategies for Management of Antiretroviral Therapy clinical trial. Am J Public Health (2010) 2.21
Nonalcoholic fatty liver disease among HIV-infected persons. J Acquir Immune Defic Syndr (2009) 1.98
Increasing rates of obesity among HIV-infected persons during the HIV epidemic. PLoS One (2010) 1.75
Trends in mortality and causes of death among women with HIV in the United States: a 10-year study. J Acquir Immune Defic Syndr (2009) 1.73
Obesity among patients with HIV: the latest epidemic. AIDS Patient Care STDS (2008) 1.69
Independent associations of insulin resistance with high whole-body intermuscular and low leg subcutaneous adipose tissue distribution in obese HIV-infected women. Am J Clin Nutr (2007) 1.63
Intervention to influence behaviors linked to risk of chronic diseases: a multisite randomized controlled trial with African-American HIV-serodiscordant heterosexual couples. Arch Intern Med (2011) 1.62
An obese body mass increases the adverse effects of HIV/AIDS on balance and gait. Phys Ther (2011) 1.41
Prevalence and correlates of elevated body mass index among HIV-positive and HIV-negative women in the Women's Interagency HIV Study. AIDS Patient Care STDS (2009) 1.17
An optimal body mass index range associated with improved immune reconstitution among HIV-infected adults initiating antiretroviral therapy. Clin Infect Dis (2011) 1.16
Obesity among HIV-infected persons: impact of weight on CD4 cell count. AIDS (2010) 1.14
HIV infection and obesity: where did all the wasting go? Antivir Ther (2012) 1.13
Short communication: from wasting to obesity: initial antiretroviral therapy and weight gain in HIV-infected persons. AIDS Res Hum Retroviruses (2012) 1.13
Obesity and dyslipidemia in behaviorally HIV-infected young women: Adolescent Trials Network study 021. Clin Infect Dis (2010) 1.11
Metabolic syndrome in HIV-infected individuals: underlying mechanisms and epidemiological aspects. AIDS Res Ther (2013) 1.04
Circulating interleukin-6, soluble CD14, and other inflammation biomarker levels differ between obese and nonobese HIV-infected adults on antiretroviral therapy. AIDS Res Hum Retroviruses (2013) 0.98
The effect of aging, nutrition, and exercise during HIV infection. HIV AIDS (Auckl) (2010) 0.97
Impact of weight on immune cell counts among HIV-infected persons. Clin Vaccine Immunol (2011) 0.92
Rising Obesity Prevalence and Weight Gain Among Adults Starting Antiretroviral Therapy in the United States and Canada. AIDS Res Hum Retroviruses (2015) 0.91
Impact of Lipodystrophy on the prevalence and components of metabolic syndrome in HIV-infected patients. BMC Infect Dis (2011) 0.90
Longitudinal anthropometric patterns among HIV-infected and HIV-uninfected women. J Acquir Immune Defic Syndr (2008) 0.89
Body mass index and CD4+ T-lymphocyte recovery in HIV-infected men with viral suppression on antiretroviral therapy. HIV Clin Trials (2011) 0.89
High risk of obesity and weight gain for HIV-infected uninsured minorities. J Acquir Immune Defic Syndr (2014) 0.89
Psychiatric and neurophysiological predictors of obesity in HIV/AIDS. Psychophysiology (2008) 0.88
Weight change after antiretroviral therapy and mortality. Clin Infect Dis (2015) 0.88
Body mass index and early CD4 T-cell recovery among adults initiating antiretroviral therapy in North America, 1998-2010. HIV Med (2015) 0.88
Hepatitis C virus infection is associated with insulin resistance among older adults with or at risk of HIV infection. AIDS (2007) 0.87
Obesity Trends and Body Mass Index Changes After Starting Antiretroviral Treatment: The Swiss HIV Cohort Study. Open Forum Infect Dis (2014) 0.85
Higher Time-Updated Body Mass Index: Association With Improved CD4+ Cell Recovery on HIV Treatment. J Acquir Immune Defic Syndr (2016) 0.85
The metabolic and cardiovascular consequences of obesity in persons with HIV on long-term antiretroviral therapy. AIDS (2016) 0.83
Changes in Body Mass Index Following HAART Initiation among HIV-Infected Women in the Women's Interagency HIV Study. J AIDS Clin Res (2014) 0.82
Changes in metabolic syndrome status after initiation of antiretroviral therapy. J Acquir Immune Defic Syndr (2015) 0.82
HIV infection and glycemic response to newly initiated diabetic medical therapy. AIDS (2012) 0.81
Serum leptin level mediates the association of body composition and serum C-reactive protein in HIV-infected persons on antiretroviral therapy. AIDS Res Hum Retroviruses (2012) 0.81
Interactive effects of HIV/AIDS, body mass, and substance abuse on the frontal brain: a P300 study. Psychiatry Res (2010) 0.80
Body mass index and the risk of incident noncommunicable diseases after starting antiretroviral therapy. HIV Med (2014) 0.80
Menthol cigarettes and the cardiovascular risks of people living with HIV. J Assoc Nurses AIDS Care (2014) 0.80
Increasing Obesity in Treated Female HIV Patients from Sub-Saharan Africa: Potential Causes and Possible Targets for Intervention. Front Immunol (2014) 0.80
The physical activity levels among people living with human immunodeficiency virus/acquired immunodeficiency syndrome receiving high active antiretroviral therapy in Rwanda. SAHARA J (2014) 0.80
Severe weight gain, lipodystrophy, dyslipidemia, and obstructive sleep apnea in a human immunodeficiency virus-infected patient following highly active antiretroviral therapy. J Cardiometab Syndr (2008) 0.79
Obesity Among HIV-Infected Adults Receiving Medical Care in the United States: Data From the Cross-Sectional Medical Monitoring Project and National Health and Nutrition Examination Survey. Medicine (Baltimore) (2015) 0.79
Nutritional status of HIV-positive patients in Niterói, Rio de Janeiro, Brazil. J Health Popul Nutr (2014) 0.79
Relationship between Body Mass Index and Mortality in HIV-Infected HAART Users in the Women's Interagency HIV Study. PLoS One (2015) 0.79
Prevalence of cardiometabolic risk factors in Hispanics living with HIV. Ethn Dis (2010) 0.78
Prevalence and Risk Factors for Overweight and Obesity among HIV-Infected Adults in Dar es Salaam, Tanzania. J Int Assoc Provid AIDS Care (2014) 0.78
High prevalence of being Overweight and Obese HIV-infected persons, before and after 24 months on early ART in the ANRS 12136 Temprano Trial. AIDS Res Ther (2016) 0.78
Weight Gain and Incident Diabetes Among HIV-Infected Veterans Initiating Antiretroviral Therapy Compared With Uninfected Individuals. J Acquir Immune Defic Syndr (2016) 0.78
Obesity is associated with race/sex disparities in diabetes and hypertension prevalence, but not cardiovascular disease, among HIV-infected adults. AIDS Res Hum Retroviruses (2015) 0.77
Food insecurity with hunger is associated with obesity among HIV-infected and at risk women in Bronx, NY. PLoS One (2014) 0.76
Incidence of Diabetes Mellitus and Obesity and the Overlap of Comorbidities in HIV+ Hispanics Initiating Antiretroviral Therapy. PLoS One (2016) 0.75
Obesity Is Not Associated with Impaired Immune Response to Influenza Vaccination in HIV-Infected Persons. AIDS Res Treat (2015) 0.75
Comprehensive and Medically Appropriate Food Support Is Associated with Improved HIV and Diabetes Health. J Urban Health (2017) 0.75
Comparative Effectiveness of Diabetic Oral Medications Among HIV-Infected and HIV-Uninfected Veterans. Diabetes Care (2016) 0.75
The role of BMI change on smoking abstinence in a sample of HIV-infected smokers. AIDS Care (2015) 0.75
Severe food insecurity is associated with overweight and increased body fat among people living with HIV in the Dominican Republic. AIDS Care (2017) 0.75
HIV and Obesity Comorbidity Increase Interleukin 6 but Not Soluble CD14 or D-Dimer. J Acquir Immune Defic Syndr (2017) 0.75
Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. N Engl J Med (2014) 7.64
Guidelines for improving entry into and retention in care and antiretroviral adherence for persons with HIV: evidence-based recommendations from an International Association of Physicians in AIDS Care panel. Ann Intern Med (2012) 7.04
DNA bar coding and pyrosequencing to identify rare HIV drug resistance mutations. Nucleic Acids Res (2007) 6.89
Electrical stimulation of the anterior nucleus of thalamus for treatment of refractory epilepsy. Epilepsia (2010) 5.64
Topographical continuity of bacterial populations in the healthy human respiratory tract. Am J Respir Crit Care Med (2011) 4.78
Optimization and validation of an 8-color intracellular cytokine staining (ICS) assay to quantify antigen-specific T cells induced by vaccination. J Immunol Methods (2007) 4.69
Standardization of cytokine flow cytometry assays. BMC Immunol (2005) 4.55
Differential Th17 CD4 T-cell depletion in pathogenic and nonpathogenic lentiviral infections. Blood (2008) 4.34
Pegylated Interferon alfa-2a monotherapy results in suppression of HIV type 1 replication and decreased cell-associated HIV DNA integration. J Infect Dis (2012) 4.24
Overestimates of survival after HAART: implications for global scale-up efforts. PLoS One (2008) 4.20
Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-Infected, treatment-experienced patients: AIDS clinical trials group 5211. J Infect Dis (2007) 3.75
Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection. N Engl J Med (2008) 3.71
The combined effect of modern highly active antiretroviral therapy regimens and adherence on mortality over time. J Acquir Immune Defic Syndr (2009) 3.67
Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine. N Engl J Med (2013) 3.24
HIV type 1 chemokine coreceptor use among antiretroviral-experienced patients screened for a clinical trial of a CCR5 inhibitor: AIDS Clinical Trial Group A5211. Clin Infect Dis (2007) 3.05
Perforin expression directly ex vivo by HIV-specific CD8 T-cells is a correlate of HIV elite control. PLoS Pathog (2010) 2.99
A time-to-prescription-refill measure of antiretroviral adherence predicted changes in viral load in HIV. J Clin Epidemiol (2004) 2.97
Pharmacy refill adherence compared with CD4 count changes for monitoring HIV-infected adults on antiretroviral therapy. PLoS Med (2008) 2.82
Risk factors and clinical impact of Klebsiella pneumoniae carbapenemase-producing K. pneumoniae. Infect Control Hosp Epidemiol (2009) 2.73
Bone disease and HIV infection. Clin Infect Dis (2005) 2.71
Lower pill burden and once-daily antiretroviral treatment regimens for HIV infection: A meta-analysis of randomized controlled trials. Clin Infect Dis (2014) 2.65
Diagnostic accuracy of CD4 cell count increase for virologic response after initiating highly active antiretroviral therapy. AIDS (2006) 2.57
IL-7 is a potent and proviral strain-specific inducer of latent HIV-1 cellular reservoirs of infected individuals on virally suppressive HAART. J Clin Invest (2005) 2.41
Bone disease in HIV infection: a practical review and recommendations for HIV care providers. Clin Infect Dis (2010) 2.20
Longitudinal evolution of bone mineral density and bone markers in human immunodeficiency virus-infected individuals. Clin Infect Dis (2003) 2.20
Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1. N Engl J Med (2015) 2.17
Preservation of T cell proliferation restricted by protective HLA alleles is critical for immune control of HIV-1 infection. J Immunol (2006) 2.17
Glucose metabolism, lipid, and body fat changes in antiretroviral-naive subjects randomized to nelfinavir or efavirenz plus dual nucleosides. AIDS (2005) 2.16
Abacavir use and risk of acute myocardial infarction and cerebrovascular events in the highly active antiretroviral therapy era. Clin Infect Dis (2011) 2.02
Analysis of lentiviral vector integration in HIV+ study subjects receiving autologous infusions of gene modified CD4+ T cells. Mol Ther (2009) 1.97
Osteoporotic fracture risk associated with cumulative exposure to tenofovir and other antiretroviral agents. AIDS (2012) 1.90
Poor immunogenicity of the H1N1 2009 vaccine in well controlled HIV-infected individuals. AIDS (2010) 1.87
Risk factors for fluconazole-resistant Candida glabrata bloodstream infections. Arch Intern Med (2009) 1.86
The virologic, immunologic, and clinical effects of interleukin 2 with potent antiretroviral therapy in patients with moderately advanced human immunodeficiency virus infection: a randomized controlled clinical trial--AIDS Clinical Trials Group 328. Arch Intern Med (2007) 1.84
The influence of patient adherence on anticoagulation control with warfarin: results from the International Normalized Ratio Adherence and Genetics (IN-RANGE) Study. Arch Intern Med (2007) 1.79
Progression of carotid artery intima-media thickening in HIV-infected and uninfected adults. AIDS (2007) 1.78
Telephone support to improve antiretroviral medication adherence: a multisite, randomized controlled trial. J Acquir Immune Defic Syndr (2008) 1.73
HIV-protease inhibitors impair vitamin D bioactivation to 1,25-dihydroxyvitamin D. AIDS (2003) 1.66
Validation and toxicity of PI3K/Akt pathway inhibition by HIV protease inhibitors in humans. Cancer Biol Ther (2008) 1.65
Massively parallel pyrosequencing in HIV research. AIDS (2008) 1.63
Safety and comparative immunogenicity of an HIV-1 DNA vaccine in combination with plasmid interleukin 12 and impact of intramuscular electroporation for delivery. J Infect Dis (2013) 1.63
Hemochromatosis gene polymorphisms, mitochondrial haplogroups, and peripheral lipoatrophy during antiretroviral therapy. J Infect Dis (2008) 1.63
Racial disparities in hypertension control, but not treatment intensification. Am J Hypertens (2009) 1.59
Cyclosporin A provides no sustained immunologic benefit to persons with chronic HIV-1 infection starting suppressive antiretroviral therapy: results of a randomized, controlled trial of the AIDS Clinical Trials Group A5138. J Infect Dis (2006) 1.57
Vitamin D deficiency is associated with type 2 diabetes mellitus in HIV infection. AIDS (2011) 1.55
Mucosal immune dysfunction in AIDS pathogenesis. AIDS Rev (2008) 1.55
Efficacy and safety of rilpivirine in treatment-naive, HIV-1-infected patients with hepatitis B virus/hepatitis C virus coinfection enrolled in the Phase III randomized, double-blind ECHO and THRIVE trials. J Antimicrob Chemother (2012) 1.54
HIV treatment adherence, drug resistance, virologic failure: evolving concepts. Infect Disord Drug Targets (2011) 1.53
Use of pharmacy refill data as a measure of antiretroviral adherence. Curr HIV/AIDS Rep (2007) 1.53
Out-of-pocket costs of HAART limit HIV treatment responses in Botswana's private sector. AIDS (2006) 1.51
Effects of potent antiretroviral therapy on free testosterone levels and fat-free mass in men in a prospective, randomized trial: A5005s, a substudy of AIDS Clinical Trials Group Study 384. Clin Infect Dis (2007) 1.47
A more precise HIV integration assay designed to detect small differences finds lower levels of integrated DNA in HAART treated patients. Virology (2008) 1.45
The HIV protease inhibitor ritonavir blocks osteoclastogenesis and function by impairing RANKL-induced signaling. J Clin Invest (2004) 1.45
Postdischarge adverse events for 1-day hospital admissions in older adults admitted from the emergency department. Ann Emerg Med (2010) 1.43
Disruption of intestinal CD4+ T cell homeostasis is a key marker of systemic CD4+ T cell activation in HIV-infected individuals. J Immunol (2010) 1.42
Patterns of antiretroviral therapy adherence and impact on HIV RNA among patients in North America. AIDS (2012) 1.42
Randomized, controlled trial of therapy interruption in chronic HIV-1 infection. PLoS Med (2004) 1.41
Peripheral and central fat changes in subjects randomized to abacavir-lamivudine or tenofovir-emtricitabine with atazanavir-ritonavir or efavirenz: ACTG Study A5224s. Clin Infect Dis (2011) 1.40
Associations among race/ethnicity, ApoC-III genotypes, and lipids in HIV-1-infected individuals on antiretroviral therapy. PLoS Med (2006) 1.40
Evidence that intermittent structured treatment interruption, but not immunization with ALVAC-HIV vCP1452, promotes host control of HIV replication: the results of AIDS Clinical Trials Group 5068. J Infect Dis (2006) 1.37
Antiretroviral failure despite high levels of adherence: discordant adherence-response relationship in Botswana. J Acquir Immune Defic Syndr (2008) 1.36
Risk factors and predictors for candidemia in pediatric intensive care unit patients: implications for prevention. Clin Infect Dis (2010) 1.36
Metabolic effects of darunavir/ritonavir versus atazanavir/ritonavir in treatment-naive, HIV type 1-infected subjects over 48 weeks. AIDS Res Hum Retroviruses (2012) 1.35
Adherence to warfarin assessed by electronic pill caps, clinician assessment, and patient reports: results from the IN-RANGE study. J Gen Intern Med (2007) 1.35
Epidemiology and impact of imipenem resistance in Acinetobacter baumannii. Infect Control Hosp Epidemiol (2009) 1.33
CD127 and CD25 expression defines CD4+ T cell subsets that are differentially depleted during HIV infection. J Immunol (2008) 1.31
Imipenem resistance in Pseudomonas aeruginosa: emergence, epidemiology, and impact on clinical and economic outcomes. Infect Control Hosp Epidemiol (2010) 1.30
Alendronate with calcium and vitamin D supplementation is safe and effective for the treatment of decreased bone mineral density in HIV. AIDS (2007) 1.29
Access to multidisciplinary cancer care: is it linked to the use of breast-conserving surgery with radiation for early-stage breast carcinoma? Cancer (2004) 1.29
Endemic babesiosis in another eastern state: New Jersey. Emerg Infect Dis (2003) 1.28
Explaining, predicting, and treating HIV-associated CD4 cell loss: after 25 years still a puzzle. JAMA (2006) 1.27
Pain, mood, and substance abuse in HIV: implications for clinic visit utilization, antiretroviral therapy adherence, and virologic failure. J Acquir Immune Defic Syndr (2012) 1.27
Long-term body fat outcomes in antiretroviral-naive participants randomized to nelfinavir or efavirenz or both plus dual nucleosides. Dual X-ray absorptiometry results from A5005s, a substudy of Adult Clinical Trials Group 384. J Acquir Immune Defic Syndr (2007) 1.27
HIV/AIDS-specific quality of life and adherence to antiretroviral therapy over time. J Acquir Immune Defic Syndr (2007) 1.26
The use of HAART is associated with decreased risk of death during initial treatment of cryptococcal meningitis in adults in Botswana. J Acquir Immune Defic Syndr (2008) 1.26
Low baseline CD4+ count is associated with greater bone mineral density loss after antiretroviral therapy initiation. Clin Infect Dis (2013) 1.23
Pain and physical and psychological symptoms in ambulatory HIV patients in the current treatment era. J Pain Symptom Manage (2011) 1.23
Medication beliefs as mediators of the health literacy-antiretroviral adherence relationship in HIV-infected individuals. AIDS Behav (2007) 1.22
Behind the cascade: analyzing spatial patterns along the HIV care continuum. J Acquir Immune Defic Syndr (2013) 1.19
Emergency department lactate is associated with mortality in older adults admitted with and without infections. Acad Emerg Med (2010) 1.17
Prevalence, risk factors, and outcomes for occult hepatitis B virus infection among HIV-infected patients. J Acquir Immune Defic Syndr (2007) 1.17
Relationship between adherence to hepatitis C virus therapy and virologic outcomes: a cohort study. Ann Intern Med (2011) 1.17
Aging and HIV infection: a comparison between older HIV-infected persons and the general population. HIV Clin Trials (2010) 1.16
Risk of hip fracture associated with hepatitis C virus infection and hepatitis C/human immunodeficiency virus coinfection. Hepatology (2012) 1.16